Jennison Associates LLC Ascendis Pharma A/S Transaction History

Jennison Associates LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 31, 2023	BUY	$86.5 - $103.97 $3.23 Million - $3.88 Million	37,363 Added 30.61%	159,434 $14.9 Million
Q2 2023 Aug 03, 2023	BUY	$69.96 - $97.84 $7.63 Million - $10.7 Million	108,991 Added 833.26%	122,071 $10.9 Million
Q1 2023 Apr 26, 2023	SELL	$104.9 - $126.78 $60,842 - $73,532	-580 Reduced 4.25%	13,080 $1.4 Million
Q4 2022 Feb 09, 2023	SELL	$99.42 - $131.97 $49,610 - $65,853	-499 Reduced 3.52%	13,660 $1.67 Million
Q3 2022 Nov 01, 2022	BUY	$84.03 - $110.23 $1.19 Million - $1.56 Million	14,159 New	14,159 $1.46 Million

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

Stay updated on Jennison Associates LLC with notifications on news.